Data gathered: July 14
Alternative Data for Spero Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 47 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,773 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.
| Price | $2.64 |
| Target Price | Sign up |
| Volume | 907,460 |
| Market Cap | $157M |
| Year Range | $0.56 - $3.04 |
| Dividend Yield | 0% |
| PE Ratio | 10.75 |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownershipJune 27 - Yahoo |
 |
Spero Therapeutics (NASDAQ:SPRO) Rating Increased to Hold at Wall Street ZenJune 21 - ETF Daily News |
 |
Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 ResultsJune 11 - SeekingAlpha |
 |
Mackenzie Financial Corp Purchases 155,656 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO)June 6 - ETF Daily News |
 |
Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 MilestoneMay 29 - Yahoo Entertainment |
|
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study GoalMay 29 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 5.9M | 0 | 0 | -14M | -15M | -0.247 |
| Q4 '24 | 9.4M | 5.1M | 9.4M | -21M | -21M | -0.367 |
| Q3 '24 | 13M | -5.7M | 13M | -17M | -19M | -0.320 |
| Q2 '24 | 6M | 2,000 | 6M | -18M | -19M | -0.330 |
| Q1 '24 | 4.2M | -5.1M | 9.3M | -13M | -14M | -0.240 |
Insider Transactions View All
| Shukla Sath filed to sell 1,886,077 shares at $0.8. February 5 '25 |
| Keutzer Timothy filed to sell 794,002 shares at $0.8. February 5 '25 |
| Mahadevia Ankit filed to sell 745,126 shares at $0.8. February 5 '25 |
| Mahadevia Ankit filed to sell 689,866 shares at $0.8. February 5 '25 |
| Shukla Sath filed to sell 1,843,291 shares at $0.8. February 5 '25 |
Similar companies
Read more about Spero Therapeutics (SPRO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Spero Therapeutics?
The Market Cap of Spero Therapeutics is $157M.
What is Spero Therapeutics' PE Ratio?
As of today, Spero Therapeutics' PE (Price to Earnings) ratio is 10.75.
What is the current stock price of Spero Therapeutics?
Currently, the price of one share of Spero Therapeutics stock is $2.64.
How can I analyze the SPRO stock price chart for investment decisions?
The SPRO stock price chart above provides a comprehensive visual representation of Spero Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Spero Therapeutics shares. Our platform offers an up-to-date SPRO stock price chart, along with technical data analysis and alternative data insights.
Does SPRO offer dividends to its shareholders?
As of our latest update, Spero Therapeutics (SPRO) does not offer dividends to its shareholders. Investors interested in Spero Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Spero Therapeutics?
Some of the similar stocks of Spero Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.